0	1	A	a	DT
2	7	novel	novel	JJ
8	25	immunosuppressive	immunosuppressive	JJ
26	32	factor	factor	NN
33	35	in	in	IN
36	42	bovine	bovine	JJ
43	52	colostrum	colostrum	NN
53	59	blocks	block	VBZ
60	70	activation	activation	NN
71	73	of	of	IN
74	77	the	the	DT
78	89	interleukin	interleukin	NN
90	91	2	2	CD
92	96	gene	gene	NN
97	105	enhancer	enhancer	NN
106	108	at	at	IN
109	112	the	the	DT
113	117	NFAT	NFAT	NNP
118	122	site	site	NN
122	123	.	.	.

125	126	A	a	DT
127	133	factor	factor	NN
134	136	in	in	IN
137	143	bovine	bovine	JJ
144	153	colostrum	colostrum	NN
154	155	(	(	(
155	164	colostrum	colostrum	NN
165	175	inhibitory	inhibitory	JJ
176	182	factor	factor	NN
182	183	,	,	,
184	187	CIF	CIF	NNP
187	188	)	)	)
189	197	inhibits	inhibit	VBZ
198	209	interleukin	interleukin	NN
210	211	2	2	CD
212	213	(	(	(
213	216	IL2	il2	NN
216	217	)	)	)
218	228	production	production	NN
229	231	in	in	IN
232	241	activated	activate	VBN
242	243	T	t	NN
244	250	helper	helper	NN
251	256	cells	cell	NNS
257	259	by	by	IN
260	268	blocking	block	VBG
269	272	the	the	DT
273	285	accumulation	accumulation	NN
286	288	of	of	IN
289	292	IL2	IL2	NNP
293	297	mRNA	mRNA	NNP
297	298	.	.	.

299	301	To	to	TO
302	311	determine	determine	VB
312	319	whether	whether	IN
320	323	CIF	cif	NN
324	330	blocks	block	NNS
331	333	at	at	IN
334	337	the	the	DT
338	343	level	level	NN
344	346	of	of	IN
347	350	IL2	il2	NN
351	364	transcription	transcription	NN
364	365	,	,	,
366	368	we	we	PRP
369	379	introduced	introduce	VBD
380	388	reporter	reporter	NN
389	397	plasmids	plasmid	NNS
398	402	into	into	IN
403	406	the	the	DT
407	412	human	human	JJ
413	414	T	t	NN
415	423	leukemia	leukemia	NN
424	428	cell	cell	NN
429	433	line	line	NN
434	440	Jurkat	jurkat	NN
441	443	by	by	IN
444	453	transient	transient	JJ
454	466	transfection	transfection	NN
466	467	.	.	.

468	473	These	these	DT
474	483	contained	contain	VBD
484	487	the	the	DT
488	498	luciferase	luciferase	NN
499	503	gene	gene	NN
504	509	under	under	IN
510	513	the	the	DT
514	521	control	control	NN
522	524	of	of	IN
525	531	either	either	CC
532	535	the	the	DT
536	541	human	human	JJ
542	545	IL2	il2	NN
546	554	upstream	upstream	JJ
555	563	enhancer	enhancer	NN
564	570	region	region	NN
571	572	(	(	(
572	580	segments	segment	NNS
581	585	-326	-326	CD
586	588	to	to	TO
589	592	+45	+45	CD
592	593	)	)	)
594	596	or	or	CC
597	602	three	three	CD
603	610	repeats	repeat	NNS
611	613	of	of	IN
614	617	the	the	DT
618	622	NFAT	NFAT	NNP
623	630	element	element	NN
631	640	contained	contain	VBN
641	647	within	within	IN
648	650	it	it	PRP
651	652	(	(	(
652	660	segments	segment	NNS
661	665	-255	-255	CD
666	668	to	to	TO
669	673	-285	-285	CD
673	674	)	)	)
674	675	.	.	.

676	686	Expression	expression	NN
687	689	of	of	IN
690	700	luciferase	luciferase	NN
701	703	in	in	IN
704	709	these	these	DT
710	715	cells	cell	NNS
716	719	was	be	VBD
720	727	induced	induce	VBN
728	730	by	by	IN
731	738	phorbol	phorbol	NN
739	748	myristate	myristate	NN
749	756	acetate	acetate	NN
757	761	plus	plus	CC
762	763	a	a	DT
764	771	calcium	calcium	NN
772	781	ionophore	ionophore	NN
781	782	.	.	.

783	786	CIF	CIF	NNP
787	796	inhibited	inhibit	VBD
797	806	induction	induction	NN
807	809	of	of	IN
810	816	either	either	CC
817	826	construct	construct	NN
827	829	as	as	IN
830	833	did	do	VBD
834	846	cyclosporine	cyclosporine	NN
846	847	,	,	,
848	853	which	which	WDT
854	856	is	be	VBZ
857	862	known	know	VBN
863	865	to	to	TO
866	871	block	block	VB
872	882	activation	activation	NN
883	885	of	of	IN
886	889	the	the	DT
890	894	NFAT	NFAT	NNP
895	902	element	element	NN
902	903	.	.	.

904	907	CIF	CIF	NNP
908	914	failed	fail	VBD
915	917	to	to	TO
918	925	inhibit	inhibit	VB
926	933	several	several	JJ
934	939	other	other	JJ
940	948	enhancer	enhancer	NN
949	957	elements	element	NNS
957	958	.	.	.

959	962	The	the	DT
963	978	NFAT-controlled	nfat-controlled	JJ
979	989	luciferase	luciferase	NN
990	994	gene	gene	NN
995	1001	system	system	NN
1002	1015	distinguishes	distinguish	VBZ
1016	1019	CIF	cif	NN
1020	1024	from	from	IN
1025	1030	other	other	JJ
1031	1032	T	t	NN
1033	1037	cell	cell	NN
1038	1048	inhibitory	inhibitory	JJ
1049	1059	activities	activity	NNS
1060	1067	present	present	JJ
1068	1070	in	in	IN
1071	1080	colostrum	colostrum	NN
1080	1081	,	,	,
1082	1084	in	in	IN
1085	1095	particular	particular	JJ
1095	1096	,	,	,
1097	1100	TGF	TGF	NNP
1101	1105	beta	beta	SYM
1106	1107	1	1	CD
1108	1111	and	and	CC
1112	1115	TGF	TGF	NNP
1116	1120	beta	beta	NN
1121	1122	2	2	CD
1123	1126	and	and	CC
1127	1130	the	the	DT
1131	1146	glucocorticoids	glucocorticoid	NNS
1146	1147	.	.	.

1148	1154	Stably	stably	RB
1155	1166	transfected	transfecte	VBN
1167	1173	Jurkat	Jurkat	NNP
1174	1179	cells	cell	NNS
1180	1187	behaved	behave	VBD
1188	1197	similarly	similarly	RB
1198	1200	to	to	TO
1201	1204	the	the	DT
1205	1216	transiently	transiently	RB
1217	1228	transfected	transfecte	VBN
1229	1233	ones	one	NNS
1234	1238	with	with	IN
1239	1246	respect	respect	NN
1247	1249	to	to	TO
1250	1260	inhibition	inhibition	NN
1261	1263	by	by	IN
1264	1267	CIF	CIF	NNP
1268	1271	and	and	CC
1272	1284	cyclosporine	cyclosporine	NN
1284	1285	.	.	.

1286	1289	The	the	DT
1290	1298	NFAT-luc	NFAT-luc	NNP
1299	1304	assay	assay	NN
1305	1307	is	be	VBZ
1308	1309	a	a	DT
1310	1316	useful	useful	JJ
1317	1326	technique	technique	NN
1327	1330	for	for	IN
1331	1334	the	the	DT
1335	1340	rapid	rapid	JJ
1340	1341	,	,	,
1342	1351	sensitive	sensitive	JJ
1352	1363	measurement	measurement	NN
1364	1366	of	of	IN
1367	1370	CIF	CIF	NNP
1371	1373	or	or	CC
1374	1379	other	other	JJ
1380	1398	immunosuppressants	immunosuppressant	NNS
1399	1403	with	with	IN
1404	1405	a	a	DT
1406	1413	similar	similar	JJ
1414	1418	mode	mode	NN
1419	1421	of	of	IN
1422	1428	action	action	NN
1428	1429	.	.	.